Form 4: Medifast Director Scott Schlackman Receives Stock Grant

Director Scott Schlackman acquired 11,680 restricted stock units as part of his annual director fee compensation.

Summary

• Director Scott Schlackman was granted 11,680 restricted stock units (RSUs) on May 26, 2026.
• The grant was issued under the Medifast, Inc. Director's Deferred Compensation Plan.
• Each unit represents the right to receive one share of common stock.
• The total beneficial ownership for the director following this transaction is 42,228.707 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Director compensation via equity aligns the interests of the board member with those of shareholders.

Negatives

• None identified.

Risks

• The value of the equity grant is subject to market volatility and the future performance of Medifast common stock.

Future Outlook

The granted units are scheduled to vest in full on May 26, 2027.

Industry Context

StockSavvy.ai notes that equity-based compensation for directors is a standard corporate governance practice intended to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of restricted stock units for director compensation is consistent with standard practices for publicly traded companies in the consumer goods and health sectors.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation event.

Next Steps

• Vesting of the 11,680 restricted stock units on May 26, 2027.

Key Dates

Keywords

Medifast, MED, Form 4, Director Compensation, Insider Transaction, Restricted Stock Units